Loading company…
Sidewinder Therapeutics develops bispecific antibody-drug conjugates for solid tumors.
Founded in 2023 and based in San Diego, US, Sidewinder Therapeutics develops bispecific antibody-drug conjugates designed to target solid tumors. In April 2026, it raised USD 137 mn in Series B funding co-led by Novartis Venture Fund and Frazier Healthcare Partners, with participation from Alexandria Venture Investments and Goldman Sachs Asset Management. The funding will support IND preparation for SWT012 and development of other programs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in